{"id":"https://openalex.org/W2606288431","doi":"https://doi.org/10.1016/j.jid.2017.02.385","title":"368 Drug utilization patterns and adherence in psoriasis patients on systemic medications","display_name":"368 Drug utilization patterns and adherence in psoriasis patients on systemic medications","publication_year":2017,"publication_date":"2017-04-12","ids":{"openalex":"https://openalex.org/W2606288431","doi":"https://doi.org/10.1016/j.jid.2017.02.385","mag":"2606288431"},"language":"en","primary_location":{"id":"doi:10.1016/j.jid.2017.02.385","doi":"https://doi.org/10.1016/j.jid.2017.02.385","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jid.2017.02.385","pdf_url":"http://www.jidonline.org/article/S0022202X17305675/pdf","source":{"id":"https://openalex.org/S28607811","display_name":"Journal of Investigative Dermatology","issn_l":"0022-202X","issn":["0022-202X","1523-1747"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Investigative Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.jidonline.org/article/S0022202X17305675/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058092661","display_name":"Erica D. Dommasch","orcid":"https://orcid.org/0000-0001-6948-2384","observed_orcids":["https://orcid.org/0000-0001-6948-2384"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E.D. Dommasch","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Dept of Dermatology, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Dept of Dermatology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091458266","display_name":"M. Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Lee","raw_affiliation_strings":["Division of Pharmacoepidemiology & Pharmacoeconomics, Dept of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology & Pharmacoeconomics, Dept of Medicine, Brigham and Women\u2019s Hospital, Boston, MA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059157113","display_name":"Joshua J. Gagne","orcid":"https://orcid.org/0000-0001-5428-9733","observed_orcids":["https://orcid.org/0000-0001-5428-9733"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Gagne","raw_affiliation_strings":["Division of Pharmacoepidemiology & Pharmacoeconomics, Dept of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology & Pharmacoeconomics, Dept of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.03898952,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"137","issue":"5","first_page":"S63","last_page":"S63"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.888700008392334,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.888700008392334,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.08250000327825546,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.9350000023841858},{"id":"https://openalex.org/keywords/drug-utilization-patterns","display_name":"drug utilization patterns","score":0.9269999861717224},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.8009999990463257},{"id":"https://openalex.org/keywords/acitretin","display_name":"acitretin","score":0.859000027179718},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":1.0},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":1.0},{"id":"https://openalex.org/keywords/medication-possession-ratio","display_name":"medication possession ratio","score":0.9580000042915344},{"id":"https://openalex.org/keywords/new-users","display_name":"new users","score":0.5059999823570251},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.6110000014305115},{"id":"https://openalex.org/keywords/age-and-sex-differences","display_name":"age and sex differences","score":0.5180000066757202},{"id":"https://openalex.org/keywords/health-insurance-claims-data","display_name":"health insurance claims data","score":0.6449999809265137},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.8080000281333923},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.35600000619888306},{"id":"https://openalex.org/keywords/outpatient-visits","display_name":"outpatient visits","score":0.3569999933242798}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9013985991477966},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.8176076412200928},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.7563555836677551},{"id":"https://openalex.org/C2778496887","wikidata":"https://www.wikidata.org/wiki/Q341500","display_name":"Acitretin","level":3,"score":0.7035079002380371},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.6745927333831787},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6424154043197632},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.561669647693634},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.4586046636104584},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4508296847343445},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.440084308385849},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.4385095238685608},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.4380122423171997},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.29345449805259705},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.16786479949951172}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jid.2017.02.385","doi":"https://doi.org/10.1016/j.jid.2017.02.385","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jid.2017.02.385","pdf_url":"http://www.jidonline.org/article/S0022202X17305675/pdf","source":{"id":"https://openalex.org/S28607811","display_name":"Journal of Investigative Dermatology","issn_l":"0022-202X","issn":["0022-202X","1523-1747"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Investigative Dermatology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jid.2017.02.385","doi":"https://doi.org/10.1016/j.jid.2017.02.385","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jid.2017.02.385","pdf_url":"http://www.jidonline.org/article/S0022202X17305675/pdf","source":{"id":"https://openalex.org/S28607811","display_name":"Journal of Investigative Dermatology","issn_l":"0022-202X","issn":["0022-202X","1523-1747"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Investigative Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2606288431.pdf","grobid_xml":"https://content.openalex.org/works/W2606288431.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2869504248","https://openalex.org/W3208072405","https://openalex.org/W4220708983","https://openalex.org/W2289328021","https://openalex.org/W2740685145","https://openalex.org/W2140855395","https://openalex.org/W2340326783","https://openalex.org/W3179952304","https://openalex.org/W2023723287","https://openalex.org/W2343114133"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2017-04-28T00:00:00"}